Dynamics of changes in the main indicators of reproductive health of women receiving chemotherapy for malignant breast tumors

  • V. A. Shamrai National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • O. I. Misiurko National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • D. I. Grebeniuk National Pirogov Memorial Medical University, Vinnytsya, Ukraine
Keywords: breast cancer, chemotherapy, chemoinduced premature ovarian failure, female reproductive system.

Abstract

Breast cancer is the second most common cancer in the world and the most common cancer among women. The use of chemotherapy as a component of comprehensive treatment leads to the development of chemoinduced premature ovarian failure. The aim of the study was to examine the dynamics of changes in the main indicators of reproductive health of women who received chemotherapy for malignant neoplasms of the breast. Reproductive health of patients (levels of antimullerian hormone, estradiol and follicle-stimulating hormone, ovarian volume and number of antral follicles) before chemotherapy and one, two, and three years after completion of chemotherapy was studied according to the purpose and objectives of the study. The obtained data were processed using the statistical software package SPSS 20.0 for Windows. Quite significant changes in the reproductive health of women in the study group were manifested in the form of menstrual disorders (oligomenorrhea, amenorrhea), involuntary abortions, inability to conceive. Changes in hormonal status were characterized by a progressive decrease in antimullerian hormone and estradiol levels and an increase in follicle-stimulating hormone levels. In addition, there was a decrease in ovarian volume and a decrease in the number of antral follicles. The dynamics of changes in the studied indicators was characterized by a sharp deterioration during the first year after chemotherapy, followed by less rapid progression. This trend is explained by dystrophic changes in ovarian tissue after chemotherapy, and at a later date – in addition, the age-related involution of the ovaries. The dynamics of changes in the main hormonal and ultrasound parameters of the ovarian reserve indicates significant impairment of reproductive function in women receiving chemotherapy for malignant neoplasms of the breast.

References

[1] Abdulrahman, G. O., Jr., & Rahman, G. A. (2012). Epidemiology of breast cancer in europe and Africa. Journal of cancer epidemiology, 2012, 915610. doi: 10.1155/2012/915610
[2] Anderson, R. A., & Su, H. I. (2020). The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer. Frontiers in endocrinology, 11, 574263. doi: 10.3389/fendo.2020.574263
[3] Bedoschi, G., Navarro, P. A., & Oktay, K. (2016). Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future oncology (London, England), 12(20), 2333-2344. doi: 10.2217/fon-2016-0176
[4] Ben-Aharon, I., Bar-Joseph, H., Tzarfaty, G., Kuchinsky, L., Rizel, S., Stemmer, S. M., & Shalgi, R. (2010). Doxorubicin-induced ovarian toxicity. Reproductive biology and endocrinology : RB&E, 8, 20. doi: 10.1186/1477-7827-8-20
[5] Busnelli, A., Vitagliano, A., Mensi, L., Acerboni, S., Bulfoni, A., Filippi, F., & Somigliana, E. (2020). Fertility in female cancer survivors: a systematic review and meta-analysis. Reproductive biomedicine online, 41(1), 96-112. doi: 10.1016/j.rbmo.2020.02.008
[6] Cardoso, F., Colleoni, M., Leo, A. D., Francia, D., Gennari, A., Gligorov, J., & Llombart, A. (2016). Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. Cancer Treatment Communications, 6(1), 1-10. doi: 10.1016/S2213-0896(16)06001-1
[7] Carioli, G., Malvezzi, M., Rodriguez, T., Bertuccio, P., Negri, E., & La Vecchia, C. (2018). Trends and predictions to 2020 in breast cancer mortality: Americas and Australasia. Breast (Edinburgh, Scotland), 37, 163-169. doi: 10.1016/j.breast.2017.12.004
[8] Chagas, C. M., & Alisaraie, L. (2019). Metabolites of Vinca Alkaloid Vinblastine: Tubulin Binding and Activation of Nausea-Associated Receptors. ACS omega, 4(6), 9784-9799. doi: 10.1021/acsomega.9b00652
[9] Cui, L., Qin, Y., Gao, X., Lu, J., Geng, L., Ding, L., … & Chen, Z. J. (2016). Antimüllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause. Fertility and sterility, 105(2), 481-485. doi: 10.1016/j.fertnstert.2015.10.017
[10] DeSantis, C. E., Ma, J., Goding Sauer, A., Newman, L. A., & Jemal, A. (2017). Breast cancer statistics, 2017, racial disparity in mortality by state. CA: a cancer journal for clinicians, 67(6), 439-448. doi: 10.3322/caac.21412
[11] Ejlertsen B. (2016). Adjuvant chemotherapy in early breast cancer. Danish medical journal, 63(5), B5222. PMID: 27127018
[12] Farokhi, F., Sadrkhanlou, R., Hasanzadeh, S. H., Sultanalinejad, F. (2007). Morphological and morphometrical study of cyclophosphamide-induced changes in the ovary and uterus in the Syrian mice. Iranian Journal of Veterinary Research, 8(4), 337-342. doi: 10.22099/ijvr.2007.11
[13] Feher, J. (2012). Quantitative Human Physiology: An Introduction (2nd ed.). Elsevier Inc.: Academic Press. doi: 10.1016/B978-0-12-382163-8.00092-X
[14] Ferley, J., Soerjomataramі, I., Ervik, M., Dikshit, R., Eser, S. (2013). GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer.
[15] Ghoncheh, M., Mohammadian-Hafshejani, A., & Salehiniya, H. (2015). Incidence and Mortality of Breast Cancer and their Relationship to Development in Asia. Asian Pacific journal of cancer prevention : APJCP, 16(14), 6081-6087. doi: 10.7314/apjcp.2015.16.14.6081
[16] Ghoncheh, M., Momenimovahed, Z., & Salehiniya, H. (2016). Epidemiology, Incidence and Mortality of Breast Cancer in Asia. Asian Pacific journal of cancer prevention : APJCP, 17(S3), 47-52. doi: 10.7314/apjcp.2016.17.s3.47
[17] Ghoncheh, M., Pournamdar, Z., & Salehiniya, H. (2016). Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pacific journal of cancer prevention : APJCP, 17(S3), 43-46. doi: 10.7314/apjcp.2016.17.s3.43
[18] Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., … & Panel members (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of oncology : official journal of the European Society for Medical Oncology, 24(9), 2206-2223. doi: 10.1093/annonc/mdt303
[19] Gomez, S. L., Von Behren, J., McKinley, M., Clarke, C. A., Shariff-Marco, S., Cheng, I., … & Glaser, S. L. (2017). Breast cancer in Asian Americans in California, 1988-2013: increasing incidence trends and recent data on breast cancer subtypes. Breast cancer research and treatment, 164(1), 139-147. doi: 10.1007/s10549-017-4229-1
[20] Hortobagyi, G. N., de la Garza Salazar, J., Pritchard, K., Amadori, D., Haidinger, R., Hudis, C. A., … & ABREAST Investigators (2005). The global breast cancer burden: variations in epidemiology and survival. Clinical breast cancer, 6(5), 391-401. doi: 10.3816/cbc.2005.n.043
[21] Kim, Y., Yoo, K. Y., & Goodman, M. T. (2015). Differences in incidence, mortality and survival of breast cancer by regions and countries in Asia and contributing factors. Asian Pacific journal of cancer prevention : APJCP, 16(7), 2857-2870. doi: 10.7314/apjcp.2015.16.7.2857
[22] Koźmiński, P., Halik, P. K., Chesori, R., & Gniazdowska, E. (2020). Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers. International journal of molecular sciences, 21(10), 3483. doi: 10.3390/ijms21103483
[23] Meirow, D., Dor, J., Kaufman, B., Shrim, A., Rabinovici, J., Schiff, E., … & Fridman, E. (2007). Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Human reproduction (Oxford, England), 22(6), 1626-1633. doi: 10.1093/humrep/dem027
[24] Momenimovahed, Z., & Salehiniya, H. (2019). Epidemiological characteristics of and risk factors for breast cancer in the world. Breast cancer (Dove Medical Press), 11, 151-164. doi: 10.2147/BCTT.S176070
[25] Morgan, S., Lopes, F., Gourley, C., Anderson, R. A., & Spears, N. (2013). Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. PloS one, 8(7), e70117. doi: 10.1371/journal.pone.0070117
[26] Moudi, M., Go, R., Yien, C. Y., & Nazre, M. (2013). Vinca alkaloids. International journal of preventive medicine, 4(11), 1231-1235. PMID: 24404355
[27] Overbeek, A., van den Berg, M. H., van Leeuwen, F. E., Kaspers, G. J., Lambalk, C. B., & van Dulmen-den Broeder, E. (2017). Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review. Cancer treatment reviews, 53, 10-24. doi: 10.1016/j.ctrv.2016.11.006
[28] Papanastasopoulos, P., & Stebbing, J. (2014). Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer research, 34(4), 1531-1535. PMID: 24692679
[29] Pribylova, O., Springer, D., Svobodnik, A., Kyr, M., Zima, T., & Petruzelka, L. (2008). Influence of chemotherapy to hormonal levels in postmenopausal breast cancer patients. Neoplasma, 55(4), 294-298. PMID: 18505339
[30] Prieto-Callejero, B., Rivera, F., Fagundo-Rivera, J., Romero, A., Romero-Martín, M., Gómez-Salgado, J., & Ruiz-Frutos, C. (2020). Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. Medicine, 99(33), e21695. doi: 10.1097/MD.0000000000021695
[31] Riddell, I. A. (2018). Cisplatin and Oxaliplatin: Our Current Understanding of Their Actions. Metal ions in life sciences, 18, /books/9783110470734/9783110470734-007/9783110470734-007.xml. doi: 10.1515/9783110470734-007
[32] Riedel, F., Hoffmann, A. S., Moderow, M., Heublein, S., Deutsch, T. M., Golatta, M., … & Hennigs, A. (2020). Time trends of neoadjuvant chemotherapy for early breast cancer. International journal of cancer, 147(11), 3049-3058. doi: 10.1002/ijc.33122
[33] Rojas, K., & Stuckey, A. (2016). Breast Cancer Epidemiology and Risk Factors. Clinical obstetrics and gynecology, 59(4), 651-672. doi: 10.1097/GRF.0000000000000239
[34] Saoji, V. A. (2008). Premature ovarian failure due to cyclophosphamide: a report of four cases in dermatology practice. Indian journal of dermatology, venereology and leprology, 74(2), 128-132. doi: 10.4103/0378-6323.39696
[35] Scheffer, J., Scheffer, B., Scheffer, R., Florencio, F., Grynberg, M., & Lozano, D. M. (2018). Are age and anti-Müllerian hormone good predictors of ovarian reserve and response in women undergoing IVF?. JBRA assisted reproduction, 22(3), 215-220. doi: 10.5935/1518-0557.20180043
[36] Schirrmacher, V. (2019). From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). International journal of oncology, 54(2), 407-419. doi: 10.3892/ijo.2018.4661
[37] Soleimani, R., Heytens, E., Darzynkiewicz, Z., & Oktay, K. (2011). Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging, 3(8), 782-793. doi: 10.18632/aging.100363
[38] Spears, N., Lopes, F., Stefansdottir, A., Rossi, V., De Felici, M., Anderson, R. A., & Klinger, F. G. (2019). Ovarian damage from chemotherapy and current approaches to its protection. Human reproduction update, 25(6), 673-693. doi: 10.1093/humupd/dmz027
[39] Torino, F., Barnabei, A., De Vecchis, L., Sini, V., Schittulli, F., Marchetti, P., & Corsello, S. M. (2014). Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. Critical reviews in oncology/hematology, 89(1), 27-42. doi: 10.1016/j.critrevonc.2013.07.007
[40] Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: a cancer journal for clinicians, 65(2), 87-108. doi: 10.3322/caac.21262
[41] Waimey, K. E., Smith, B. M., Confino, R., Jeruss, J. S., & Pavone, M. E. (2015). Understanding Fertility in Young Female Cancer Patients. Journal of women's health (2002), 24(10), 812-818. doi: 10.1089/jwh.2015.5194
[42] Williams, L. J., Fletcher, E., Douglas, A., Anderson, E., McCallum, A., Simpson, C. R., … & Wild, S. H. (2018). Retrospective cohort study of breast cancer incidence, health service use and outcomes in Europe: a study of feasibility. European journal of public health, 28(2), 327-332. doi: 10.1093/eurpub/ckx127
[43] Xiao, S., Zhang, J., Liu, M., Iwahata, H., Rogers, H. B., & Woodruff, T. K. (2017). Doxorubicin Has Dose-Dependent Toxicity on Mouse Ovarian Follicle Development, Hormone Secretion, and Oocyte Maturation. Toxicological sciences : an official journal of the Society of Toxicology, 157(2), 320-329. doi: 10.1093/toxsci/kfx047
[44] Youlden, D. R., Cramb, S. M., Yip, C. H., & Baade, P. D. (2014). Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer biology & medicine, 11(2), 101-115. doi: 10.7497/j.issn.2095-3941.2014.02.005
Published
2021-06-26
How to Cite
Shamrai, V. A., Misiurko, O. I., & Grebeniuk, D. I. (2021). Dynamics of changes in the main indicators of reproductive health of women receiving chemotherapy for malignant breast tumors. Biomedical and Biosocial Anthropology, (43), 5-12. https://doi.org/10.31393/bba43-2021-01